Clinical Review
Non–Daily-Dosed Rosuvastatin in Statin-Intolerant Veterans
Fed Pract. 2014 February;31(2):24-28
Author and Disclosure Information
Lisa Grove, PharmD; Emily McGlamery, PharmD; Jeremy W. Hall, PharmD; and Stephanie Davis, PharmD
The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, also known as statins, are the treatment of choice for hyperlipidemia.(1) Many patients, however, are unable to tolerate statins and subsequently discontinue therapy. The reported incidence of statin intolerance varies widely in the literature. A recent review estimated that 10% to 15% of statin users experience some type of myopathy, which is one of the most common reasons for discontinuation.(2)